These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26285159)

  • 1. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma.
    Zhao L; Jiang R; Xu M; Zhu P; Mo XM; Wang N; Chen GG; Liu ZM
    Clin Endocrinol (Oxf); 2016 May; 84(5):748-55. PubMed ID: 26285159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
    Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
    Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior.
    Dai YJ; Qiu YB; Jiang R; Xu M; Liao LY; Chen GG; Liu ZM
    Cell Oncol (Dordr); 2018 Jun; 41(3):269-282. PubMed ID: 29368272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of HIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Dong CR; Jiang R; Tang C; Yang L; Jiang QF; Chen GG; Liu ZM
    Int J Clin Exp Pathol; 2014; 7(1):322-30. PubMed ID: 24427353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
    Kim YS; Kim JS; Bae JS; Park WC
    World J Surg Oncol; 2013 May; 11():99. PubMed ID: 23687957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
    Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
    Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
    Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
    J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
    Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
    Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
    Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between BRAFV600E, NF-κB and TgAb expression in papillary thyroid carcinoma.
    Li W; Ming H; Sun D; Li W; Wang D; Zhang G; Tan J
    Pathol Res Pract; 2017 Mar; 213(3):183-188. PubMed ID: 28214213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of p53-binding protein 1 (53BP1) expression in thyroid papillary microcarcinoma: association with BRAFV600E mutation status.
    Mussazhanova Z; Matsuda K; Naruke Y; Mitsutake N; Stanojevic B; Rougounovitch T; Saenko V; Suzuki K; Nishihara E; Hirokawa M; Ito M; Nakashima M
    Histopathology; 2013 Nov; 63(5):726-34. PubMed ID: 24004175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation.
    Park WS; Chung KW; Young MS; Kim SK; Lee YJ; Lee EK
    Anticancer Res; 2013 Oct; 33(10):4357-64. PubMed ID: 24123003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.
    Sykorova V; Dvorakova S; Ryska A; Vcelak J; Vaclavikova E; Laco J; Kodetova D; Kodet R; Cibula A; Duskova J; Hlobilkova A; Astl J; Vesely D; Betka J; Hoch J; Smutny S; Cap J; Vlcek P; Novak Z; Bendlova B
    J Endocrinol Invest; 2010 May; 33(5):318-24. PubMed ID: 20009493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.